Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05933395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Study acronym: GERTRUDE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Start date: Oct 10, 2023 to Sep 23, 2024v4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Sep 2030 to Oct 2030
    • Study completion date: Sep 2031 to Oct 2031
    • Start date changed from estimate of Sep 2023 to Oct 10, 2023
    • Site details revised
  4. Start date: Jul 2023 to Sep 2023
    • Primary completion date: Jul 2030 to Sep 2030
    • Study completion date: Jul 2031 to Sep 2031
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Trial Details
NCT Number NCT05933395
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions
(from sponsor)		 Advanced Breast Cancer
Related terms Neoplasm Metastasis
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov